Merck (MRK) Trading Higher After Strong Q3 Earnings

Rate this post
Merck (MRK) Trading Higher After Strong Q3 Earnings

Merck & Co., Inc. (MRK) is up nearly 1% in pre-market trade Tuesday after reporting a third-quarter 2020 profit of $1.74 per share, $0.31 more than consensus projections. Revenue increased 1.2% year on year to $12.55 billion, above estimates. The pharmaceutical company capped off the upbeat report by increasing its 2020 outlook by more than 10%, but the lackluster post-news response reflects persistent market disinterest.

Key Takeaways

  • Merck exceeded third-quarter top- and bottom-line expectations and boosted its full-year outlook.
  • The lackluster post-news response reflects continued investor disinterest.
  • The dividend yield of 3.07% is more appealing than the mixed price trend.

Merck has a robust pipeline of cancer, pain management, and HIV therapies, but it entered the COVID-19 search later than its competitors and has just recently begun early studies. Merck shares surged alongside pandemic-focused equities in the middle of the year, when the broad sector drew a strong offer, but have since settled into a bearish pattern, slicing through support at the 50- and 200-day exponential moving averages (EMAs).The $81.50 level, or around two points over this morning’s starting print, indicates the dividing line between bull and bear power in this price structure.

Merck is rated a “Moderate Buy” by Wall Street, with eight “Buy” and three “Hold” recommendations. No experts advise owners to liquidate their holdings and exit the market. Price targets presently range from $84 to $105, with the stock expected to start the day around $4 below the low goal. This gap illustrates the current preference for tech and other growth industries over traditional pharma equities. Nonetheless, the 3.09% projected dividend yield keeps existing stockholders satisfied.

  Trading Book

The guidance of a public business is its report to shareholders on the profits it expects to accomplish in the next quarter or fiscal year. The report, also known as earnings guidance or a forward-looking statement, usually contains revenue predictions, predicted profitability, and capital investment estimates.

Merck Monthly Chart (2000 – 2020)

TradingView.com

A multi-year upswing peaked in November 2000 at $96.69, a high that was not challenged for the following 20 years, until a sustained decline sliced three wide selling waves into March 2009’s 13-year low in the mid-$20s. In 2014, a slow-motion recovery completed a round trip to the 2007 swing high in the low $60s, resulting in a brief rally followed by a failed breakout that strengthened resistance.

A second breakthrough after the 2016 presidential election failed to live up to expectations, peaking in the mid-$60s in the first quarter of 2017. In April 2018, the stock hit a two-year low of $52.83, representing the biggest buying opportunity of the decade, ahead of a steady rise that completed the three-year breakout effort in the third quarter. The uptrend continued to provide good gains until December 2019, when it reversed within four points of the 2000 high.

Merck Short-Term Outlook

During the first quarter, the stock fell to a two-year low and rallied in two rally waves before reversing at the.786 Fibonacci selloff retracement level in September. It has now entered a monthly stochastic sell cycle, indicating mixed performance until the first quarter of 2021. More crucially, accumulation indicators have fallen after reaching an all-time high in December 2019, indicating that institutions have reduced their position in favor of alternative chances.

  Factors That Influence Black-Scholes Warrant Dilution

In the medium term, Merck stock is very oversold on a weekly basis, enhancing the prospect of an intermediate rebound against a buzzsaw of resistance in the mid- to upper-$80s. A purchasing surge over the September high of $87.80 is required to strengthen the longer-term picture and set the stage for a test of the 2019 high. Unfortunately, it does not seem that this will be the case in the fourth quarter.

Oversold is a circumstance in which an asset has traded at a lower price and has the possibility for a price rebound. Because an oversold state may linger for a long period, being oversold does not guarantee that a price rise will occur soon or at all. Many technical indicators distinguish between oversold and overbought levels.

The Bottom Line

Merck stock is up following a great third-quarter earnings release, but market indifference is expected to prevail.

Disclosure: At the time of publishing, the author had no investments in the aforementioned securities.

You are looking for information, articles, knowledge about the topic Merck (MRK) Trading Higher After Strong Q3 Earnings on internet, you do not find the information you need! Here are the best content compiled and compiled by the achindutemple.org team, along with other related topics such as: Trading.

Similar Posts